Different inhibitory concentrations (IC) of cisplatin in HeLa, SiHa shREV3L cells and control cells.

The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro.

Eichholtz-Wirth, H.
Hietel, B.

January 1986

Clonogenic survival of HeLa, Chinese hamster and HaK cells after treatment with a range of cisplatin...

HCT116 clones vary in sensitivity to cisplatin.

Hong Shen (166278)
Ricardo E. Perez (396834)
Batzaya Davaadelger (396835)
Carl G. Maki (396836)

April 2013

A) HCT116 cells were plated at single cell density and ten individual clones (designated D...

Levels of TNF-α, caspase-3, IL-6, and superoxide dismutase in HEK293 cells lysates treated with vehicle, cisplatin (Cis, 10 μM), cisplatin+pioglitazone (PIO, 10 μM), cisplatin+fenofibrate (Feno, 10 μM), cisplatin+pioglitazone+fenofibrate, cisplatin+thalidomide (Thalid, 10 μM), and cisplatin+pioglitazone+fenofibrate+thalidomide.

Mai M. Helmy (822134)
Maged W. Helmy (822135)
Mahmoud M. El-Mas (551540)

November 2015

All drugs were incubated for 24 hr. Values are means±S.E.M. of 5 replicas. *, +, <s...

The half-maximal inhibitory concentration of cisplatin.

Sanne R. Martens-de Kemp (403702)
Simone U. Dalm (403703)
Fiona M. J. Wijnolts (403704)
Arjen Brink (403705)
Richard J. Honeywell (403706)
Godefridus J. Peters (121184)
Boudewijn J. M. Braakhuis (403707)
Ruud H. Brakenhoff (61466)

April 2013

Nineteen HNSCC cell lines were continuously treated with 18 different concentrations of cisplatin...

Inhibitory concentrations 50 (IC50) and CI95 for cisplatin and compound 12 in HCT116 and A549 cells.

Khaled H. Barakat (293854)
Lars P. Jordheim (193433)
Rolando Perez-Pineiro (293856)
David Wishart (13381)
Charles Dumontet (193436)
Jack A. Tuszynski (160860)

February 2013

Results are mean values from three independent experiments ± standard error of means. Synergy is ...

The inhibitory effects of cisplatin on the proliferative capacity of cisplatin resistant NSCLC cells.

Martin P. Barr (288251)
Steven G. Gray (111201)
Andreas C. Hoffmann (288252)
Ralf A. Hilger (288254)
Juergen Thomale (288256)
John D. O’Flaherty (288257)
Dean A. Fennell (111225)
Derek Richard (288258)
John J. O’Leary (288259)
Kenneth J. O’Byrne (288260)

February 2013

Parent (PT) and cisplatin resistant (CisR) cell lines were treated with increasing concentrations...

Cells exhibit increased fold changes in IC50 concentrations following long-term exposure to cisplatin.

Martin P. Barr (288251)
Steven G. Gray (111201)
Andreas C. Hoffmann (288252)
Ralf A. Hilger (288254)
Juergen Thomale (288256)
John D. O’Flaherty (288257)
Dean A. Fennell (111225)
Derek Richard (288258)
John J. O’Leary (288259)
Kenneth J. O’Byrne (288260)

February 2013

Following maintenance of cisplatin treated sublines in culture for 6 months with cisplatin, IC<su...

p53 reporter activity changes in HeLa, SiHa and CaSki cells.

Kemal Alpay (620277)
Mehdi Farshchian (620278)
Johanna Tuomela (620279)
Jouko Sandholm (620280)
Kaappo Aittokallio (620281)
Elina Siljamäki (279419)
Marko Kallio (620282)
Veli-Matti Kähäri (145925)
Sakari Hietanen (620283)

August 2014

The results are given in fold-change. The concentrations used were MX 0.6 µM, 1 µM and 1 µM in He...

Summary

Britta Stordal
Mary Davey

December 2014

Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resist...

Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration

Fischel, Jean Louis
Formento, Patricia
Gioanni, Jeanine
Milano, Gérard
Troger, Veronique

January 1992

The present study was designed to analyse the cytotoxic effect of cisplatin in vitro as a function o...

NSCLC cell lines and bladder cell line, HTB9, are shown for various concentrations of cisplatin with the presence and absence of mithramycin.

Lidija K. Gorsic (214773)
Amy L. Stark (184279)
Heather E. Wheeler (174954)
Shan S. Wong (499784)
Hae K. Im (499785)
M. Eileen Dolan (125333)

December 2013

Square shape represents cisplatin concentrations alone, while the triangle represents cisplatin w...

The half maximal inhibitory concentration (IC50) in each group of breast cancer cells.

Moltira Promkan (285292)
Sumana Dakeng (285295)
Subhas Chakrabarty (285298)
Oliver Bögler (5651335)
Pimpicha Patmasiriwat (285301)

February 2013

The half maximal inhibitory concentration (IC50) in each group of breast cancer cells....

Cisplatin resistant cells accumulate in the G0/G1 phase of the cell cycle.

Martin P. Barr (288251)
Steven G. Gray (111201)
Andreas C. Hoffmann (288252)
Ralf A. Hilger (288254)
Juergen Thomale (288256)
John D. O’Flaherty (288257)
Dean A. Fennell (111225)
Derek Richard (288258)
John J. O’Leary (288259)
Kenneth J. O’Byrne (288260)

February 2013

Parent and Cisplatin resistant NSCLC cells were treated with cisplatin for 24 h. Cell cycle distr...

CELLULAR BASIS FOR DIFFERENTIAL SENSITIVITY TO CISPLATIN IN HUMAN GERM-CELL TUMOR AND COLON-CARCINOMA CELL-LINES

SARK, MWJ
TIMMERBOSSCHA, H
MEIJER, C
UGES, DRA
SLUITER, WJ
PETERS, WHM
MULDER, NH
DEVRIES, EGE

April 1995

Cisplatin (CDDP) resistance mechanisms were studied in a model of three germ cell tumour and three c...

Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines

Welters, Marij J.P.
Fichtinger-Schepman, Anne Marie J.
Baan, Robert A.
Hermsen, Mario A.J.A.
Van Der Vijgh, Wim J.F.
Cloos, Jacqueline
Braakhuis, Boudewijn J.M.

June 1997

Patients with head and neck squamous cell carcinoma (HNSCC) treated with cisplatin show a large inte...

The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro.

Eichholtz-Wirth, H.
Hietel, B.

January 1986

Clonogenic survival of HeLa, Chinese hamster and HaK cells after treatment with a range of cisplatin...

HCT116 clones vary in sensitivity to cisplatin.

Hong Shen (166278)
Ricardo E. Perez (396834)
Batzaya Davaadelger (396835)
Carl G. Maki (396836)

April 2013

A) HCT116 cells were plated at single cell density and ten individual clones (designated D...

Levels of TNF-α, caspase-3, IL-6, and superoxide dismutase in HEK293 cells lysates treated with vehicle, cisplatin (Cis, 10 μM), cisplatin+pioglitazone (PIO, 10 μM), cisplatin+fenofibrate (Feno, 10 μM), cisplatin+pioglitazone+fenofibrate, cisplatin+thalidomide (Thalid, 10 μM), and cisplatin+pioglitazone+fenofibrate+thalidomide.

Mai M. Helmy (822134)
Maged W. Helmy (822135)
Mahmoud M. El-Mas (551540)

November 2015

All drugs were incubated for 24 hr. Values are means±S.E.M. of 5 replicas. *, +, <s...

The half-maximal inhibitory concentration of cisplatin.

Sanne R. Martens-de Kemp (403702)
Simone U. Dalm (403703)
Fiona M. J. Wijnolts (403704)
Arjen Brink (403705)
Richard J. Honeywell (403706)
Godefridus J. Peters (121184)
Boudewijn J. M. Braakhuis (403707)
Ruud H. Brakenhoff (61466)

April 2013

Nineteen HNSCC cell lines were continuously treated with 18 different concentrations of cisplatin...

Inhibitory concentrations 50 (IC50) and CI95 for cisplatin and compound 12 in HCT116 and A549 cells.

Khaled H. Barakat (293854)
Lars P. Jordheim (193433)
Rolando Perez-Pineiro (293856)
David Wishart (13381)
Charles Dumontet (193436)
Jack A. Tuszynski (160860)

February 2013

Results are mean values from three independent experiments ± standard error of means. Synergy is ...

The inhibitory effects of cisplatin on the proliferative capacity of cisplatin resistant NSCLC cells.

Martin P. Barr (288251)
Steven G. Gray (111201)
Andreas C. Hoffmann (288252)
Ralf A. Hilger (288254)
Juergen Thomale (288256)
John D. O’Flaherty (288257)
Dean A. Fennell (111225)
Derek Richard (288258)
John J. O’Leary (288259)
Kenneth J. O’Byrne (288260)

February 2013

Parent (PT) and cisplatin resistant (CisR) cell lines were treated with increasing concentrations...

Cells exhibit increased fold changes in IC50 concentrations following long-term exposure to cisplatin.

Martin P. Barr (288251)
Steven G. Gray (111201)
Andreas C. Hoffmann (288252)
Ralf A. Hilger (288254)
Juergen Thomale (288256)
John D. O’Flaherty (288257)
Dean A. Fennell (111225)
Derek Richard (288258)
John J. O’Leary (288259)
Kenneth J. O’Byrne (288260)

February 2013

Following maintenance of cisplatin treated sublines in culture for 6 months with cisplatin, IC<su...

p53 reporter activity changes in HeLa, SiHa and CaSki cells.

Kemal Alpay (620277)
Mehdi Farshchian (620278)
Johanna Tuomela (620279)
Jouko Sandholm (620280)
Kaappo Aittokallio (620281)
Elina Siljamäki (279419)
Marko Kallio (620282)
Veli-Matti Kähäri (145925)
Sakari Hietanen (620283)

August 2014

The results are given in fold-change. The concentrations used were MX 0.6 µM, 1 µM and 1 µM in He...

Summary

Britta Stordal
Mary Davey

December 2014

Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resist...

Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration

Fischel, Jean Louis
Formento, Patricia
Gioanni, Jeanine
Milano, Gérard
Troger, Veronique

January 1992

The present study was designed to analyse the cytotoxic effect of cisplatin in vitro as a function o...

NSCLC cell lines and bladder cell line, HTB9, are shown for various concentrations of cisplatin with the presence and absence of mithramycin.

Lidija K. Gorsic (214773)
Amy L. Stark (184279)
Heather E. Wheeler (174954)
Shan S. Wong (499784)
Hae K. Im (499785)
M. Eileen Dolan (125333)

December 2013

Square shape represents cisplatin concentrations alone, while the triangle represents cisplatin w...

The half maximal inhibitory concentration (IC50) in each group of breast cancer cells.

Moltira Promkan (285292)
Sumana Dakeng (285295)
Subhas Chakrabarty (285298)
Oliver Bögler (5651335)
Pimpicha Patmasiriwat (285301)

February 2013

The half maximal inhibitory concentration (IC50) in each group of breast cancer cells....

Cisplatin resistant cells accumulate in the G0/G1 phase of the cell cycle.

Martin P. Barr (288251)
Steven G. Gray (111201)
Andreas C. Hoffmann (288252)
Ralf A. Hilger (288254)
Juergen Thomale (288256)
John D. O’Flaherty (288257)
Dean A. Fennell (111225)
Derek Richard (288258)
John J. O’Leary (288259)
Kenneth J. O’Byrne (288260)

February 2013

Parent and Cisplatin resistant NSCLC cells were treated with cisplatin for 24 h. Cell cycle distr...

CELLULAR BASIS FOR DIFFERENTIAL SENSITIVITY TO CISPLATIN IN HUMAN GERM-CELL TUMOR AND COLON-CARCINOMA CELL-LINES

SARK, MWJ
TIMMERBOSSCHA, H
MEIJER, C
UGES, DRA
SLUITER, WJ
PETERS, WHM
MULDER, NH
DEVRIES, EGE

April 1995

Cisplatin (CDDP) resistance mechanisms were studied in a model of three germ cell tumour and three c...

Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines

Welters, Marij J.P.
Fichtinger-Schepman, Anne Marie J.
Baan, Robert A.
Hermsen, Mario A.J.A.
Van Der Vijgh, Wim J.F.
Cloos, Jacqueline
Braakhuis, Boudewijn J.M.

June 1997

Patients with head and neck squamous cell carcinoma (HNSCC) treated with cisplatin show a large inte...

The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro.

Eichholtz-Wirth, H.
Hietel, B.

January 1986

Clonogenic survival of HeLa, Chinese hamster and HaK cells after treatment with a range of cisplatin...

HCT116 clones vary in sensitivity to cisplatin.

Hong Shen (166278)
Ricardo E. Perez (396834)
Batzaya Davaadelger (396835)
Carl G. Maki (396836)

April 2013

A) HCT116 cells were plated at single cell density and ten individual clones (designated D...

Levels of TNF-α, caspase-3, IL-6, and superoxide dismutase in HEK293 cells lysates treated with vehicle, cisplatin (Cis, 10 μM), cisplatin+pioglitazone (PIO, 10 μM), cisplatin+fenofibrate (Feno, 10 μM), cisplatin+pioglitazone+fenofibrate, cisplatin+thalidomide (Thalid, 10 μM), and cisplatin+pioglitazone+fenofibrate+thalidomide.

Mai M. Helmy (822134)
Maged W. Helmy (822135)
Mahmoud M. El-Mas (551540)

November 2015

All drugs were incubated for 24 hr. Values are means±S.E.M. of 5 replicas. *, +, <s...

Different inhibitory concentrations (IC) of cisplatin in HeLa, SiHa shREV3L cells and control cells.

Abstract

Extracted data

Different inhibitory concentrations (IC) of cisplatin in HeLa, SiHa shREV3L cells and control cells.

Abstract

Extracted data

Related items

Related items